Date | Price Target | Rating | Analyst |
---|---|---|---|
4/12/2024 | $5.00 | Buy | Craig Hallum |
1/20/2023 | Buy → Neutral | BTIG Research | |
1/17/2023 | $3.75 | Overweight → Equal-Weight | Stephens |
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 300 points on Wednesday. Shares of ASML Holding N.V. (NASDAQ:ASML) fell in today's pre-market trading following the release of second-quarter results. The Dutch company reported a second-quarter net income of 1.6 billion euros ($1.75 billion) on revenues of 6.2 billion euros ($6.77 billion), surpassing analysts' expectations of 1.41 billion euros on revenue of 6.04 billion euros, Reuters reported on Wednesday. The new bookings for the quarter stood at 5.6 billion euros ($6.11 billion), a significant increase from the 3.6 billion euros in the first quarter of 2024. ASML shares dipped 6.8% to $995.90 i
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave. Bloom Energy said it entered into a partnership to deploy its proprietary fuel cells to generate on-site power for CoreWeave at a high-performance data center in Illinois. Bloom Energy shares jumped 12.1% to $16.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Shimmick Corporation (NASDAQ:SHIM) gained 53% to $3.09 in pre-market trading after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project. Aptevo Therapeutics Inc. (NA
The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Earth Science Tech The Trade: Earth Science Tech, Inc. (OTC:ETST) Director Yovan Arturo Sanchez bought a total of 10,500 shares at an average price of $0.10. To acquire these shares, it cost around $1,050. What's Happening: On Jan. 29, Earth Scien
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep
First Quarter Product Revenue Increased 24% from Prior Year Quarter Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Months Ended March 31, Change 2024 2023 $ % Product Revenue $ 38,365 $ 30,974 $ 7,391 24% Government Contract Revenue 5,030 7,502 (2,472 ) -33% Total Revenue $ 43,395 $
First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h
S-8 - CERUS CORP (0001020214) (Filer)
10-Q - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h
Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00
BTIG Research downgraded Cerus from Buy to Neutral
Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75